Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors

Ítems similars

• ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation
  per: Pidala, Joseph, et al.
  Publicat: (2011)
• Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience
  per: Nelson, R, et al.
  Publicat: (2015)
• Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies
  per: Eapen, Mary, et al.
  Publicat: (2014)
• A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
  per: Pidala, Joseph, et al.
  Publicat: (2012)
• Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
  per: Koreth, John, et al.
  Publicat: (2009)